Skip to main content

Bionano Genomics, Inc. (BNGO) Stock Forecast 2025 - AI Price Prediction & Analysis


Bionano Genomics, Inc. (BNGO) AI Stock Price Forecast & Investment Analysis

Bionano Genomics, Inc. Stock Price Chart and Technical Analysis

Loading Bionano Genomics, Inc. interactive price chart and technical analysis...

Bionano Genomics, Inc. (BNGO) - Comprehensive Stock Analysis & Investment Research

Deep dive into Bionano Genomics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Bionano Genomics, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Bionano Genomics, Inc.: Bionano Genomics, Inc. operates in the Industrial Applications and Services sector, making it an emerging small-cap investment.

Bionano Genomics, Inc. (Stock Symbol: BNGO) is a leading company in the Industrial Applications and Services sector , specifically operating within the Laboratory Analytical Instruments industry.

The organization employs approximately 313 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Bionano Genomics, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Bionano Genomics, Inc.: With $27M in annual revenue and -450.7% net margin, the company demonstrates developing profitability.

Annual Revenue: $27 million generating a -450.7% net profit margin .

Market Capitalization: $7 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -27.4% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Bionano Genomics, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

For Bionano Genomics, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Bionano Genomics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Bionano Genomics, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Bionano Genomics, Inc.: Market positioning analysis based on available financial and operational metrics.

Bionano Genomics, Inc. strategically competes in the highly dynamic Laboratory Analytical Instruments marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 18.0% gross margin, indicating strong pricing power and operational efficiency.

Bionano Genomics, Inc. (BNGO) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Bionano Genomics, Inc. stock analysis.

Loading Bionano Genomics, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Bionano Genomics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Bionano Genomics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Bionano Genomics, Inc.: With a P/E ratio of -0.04, the market sees the stock as potentially undervalued.

P/E Ratio -0.04x
P/B Ratio 0.16x
Market Cap $7M
EPS $-90.58
Book Value/Share $11.59
Revenue/Share $7.02
FCF/Share $-0.49
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Bionano Genomics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Bionano Genomics, Inc.: An ROE of -27.4% indicates room for improvement in shareholder value creation.

ROE -27.4%
ROA -25.2%
ROIC -26.3%
Gross Margin 18.0%
Operating Margin -467.5%
Net Margin -450.7%
EBT Margin -478.6%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Bionano Genomics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Bionano Genomics, Inc.: A current ratio of 12.99 indicates strong liquidity.

Current Ratio 12.99x
Quick Ratio 11.90x
D/E Ratio 0.03x
Financial Leverage 1.11x
Interest Coverage -243.8x
Working Capital $38M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Bionano Genomics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Bionano Genomics, Inc.: Free cash flow of $-93M indicates cash challenges that need attention.

Operating Cash Flow $-91M
Free Cash Flow $-93M
Capital Spending $-2M
FCF/Sales -453.1%
CapEx/Sales 11.8%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Bionano Genomics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Bionano Genomics, Inc.: An asset turnover of 0.06x suggests room for improvement in asset utilization.

Asset Turnover 0.06x
Receivables Turnover 5.5x
Inventory Turnover 1.7x
Fixed Assets Turnover 1.4x
Days Sales Outstanding 67 days
Days Inventory 209 days
Payables Period 95 days
Cash Conversion Cycle 181 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Bionano Genomics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Bionano Genomics, Inc.: With annual revenue of $27M, Bionano Genomics, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $27M
R&D Expense $33M
SG&A Expense $338M
Cost of Goods Sold $34M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 70%
Cash & Short-term Investments 62%
Total Liabilities 11%
Short-term Debt 66%
Accounts Receivable 2%
Inventory 5%
Dividend & Shareholder Information
Shares Outstanding 4M
Growth Metrics (YoY)
EPS Growth -67.0%

Latest Bionano Genomics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Bionano Genomics, Inc. (BNGO) stock price and investment outlook.

, source: Yahoo Finance

Bionano Genomics, Inc. (NASDAQ:BNGO) is among the best fundamentally strong penny stocks to buy right now. Bionano Genomics, Inc. (NASDAQ:BNGO) has launched a public offering of 5 million shares, ...

, source: Benzinga.com

Bionano Genomics BNGO is set to give its latest quarterly earnings report on Thursday, 2025-08-14. Here's what investors need to know before the announcement. Analysts estimate that Bionano Genomics ...

Bionano Genomics, Inc. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of Bionano Genomics, Inc. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
A Unlock Forecast - 30 Days FREE Trial $39604M 32.5x 6.2x
ASTC Unlock Forecast - 30 Days FREE Trial $7M 28.9x 0.3x
AVTR Unlock Forecast - 30 Days FREE Trial $9931M 14.5x 1.6x
BIO Unlock Forecast - 30 Days FREE Trial $8619M 27.0x 1.2x
BIO-B Unlock Forecast - 30 Days FREE Trial $7860M 24.6x 1.1x
BNGO Unlock Forecast - 30 Days FREE Trial $7M 0.0x 0.2x
BRKR Unlock Forecast - 30 Days FREE Trial $5796M 72.8x 3.3x
CTKB Unlock Forecast - 30 Days FREE Trial $502M 82.0x 1.3x
EYPT Unlock Forecast - 30 Days FREE Trial $792M -4.4x 3.2x
HBIO Unlock Forecast - 30 Days FREE Trial $17M -8.3x 1.1x
ILMN Unlock Forecast - 30 Days FREE Trial $15154M 12.1x 6.7x
LAB Unlock Forecast - 30 Days FREE Trial $485M -2.4x 1.1x
LCTC Unlock Forecast - 30 Days FREE Trial $9M x 1.5x
NAUT Unlock Forecast - 30 Days FREE Trial $123M -3.8x 0.7x
PACB Unlock Forecast - 30 Days FREE Trial $493M -1.5x 8.0x
PRPO Unlock Forecast - 30 Days FREE Trial $26M -1.2x 1.8x
RPID Unlock Forecast - 30 Days FREE Trial $137M -0.9x 2.5x
RVTY Unlock Forecast - 30 Days FREE Trial $10935M 38.3x 1.5x
SEER Unlock Forecast - 30 Days FREE Trial $137M -2.0x 0.4x
TXG Unlock Forecast - 30 Days FREE Trial $1538M -8.6x 2.0x
WAT Unlock Forecast - 30 Days FREE Trial $19913M 30.1x 9.2x

Frequently Asked Questions - Bionano Genomics, Inc. Stock Forecast

How accurate are Bionano Genomics, Inc. stock predictions?

Our AI model demonstrates 77% historical accuracy for BNGO predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence Bionano Genomics, Inc. stock price forecasts?

Our analysis considers Bionano Genomics, Inc.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Bionano Genomics, Inc. a good investment in 2025?

Based on our AI analysis, Bionano Genomics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Bionano Genomics, Inc. forecasts updated?

Bionano Genomics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Bionano Genomics, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Bionano Genomics, Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...